# INV-8989

Source: https://onco.cc/drugs/inv-8989/  
OnCo record `inv-8989` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

INV-8989 is an experimental form not stated by the company or the registry from Shenzhen Ionova Life Sciences, in phase 1 trials for colorectal cancer, non-small cell lung cancer and pancreatic adenocarcinoma and other cancers.

## Summary

INV-8989 is a form not stated by the company or the registry from Shenzhen Ionova Life Sciences. Tested in solid tumours harbouring KRAS G12D mutations; neither the registry nor the company website states the molecule's mechanism or modality. Its furthest stage is phase 1, for colorectal cancer, non-small cell lung cancer, pancreatic adenocarcinoma and ovarian cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 first-in-human, recruiting, started 2026-06-01 (registry). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: INV-8989
- Modality: Form not stated by the company or the registry
- Mechanism: Tested in solid tumours harbouring KRAS G12D mutations; neither the registry nor the company website states the molecule's mechanism or modality.

## Sources

- Shenzhen Ionova Life Sciences: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07610798
- Shenzhen Ionova Life Sciences: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07610798
- ClinicalTrials.gov: trials of INV-8989: https://clinicaltrials.gov/search?intr=INV-8989

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- companies: [Shenzhen Ionova Life Sciences](https://onco.cc/companies/shenzhen-ionova-life-sciences/)
- trials: [A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations](https://onco.cc/trials/nct07610798/)

---
JSON: https://onco.cc/api/v1/entities/inv-8989.json